Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Michael Lahn, Stephan Herbertz, J. Scott Sawyer, Anja J Stauber, Ivelina Gueorguieva, Kyla E Driscoll, Shawn T Estrem, Ann L Cleverly, Durisala Desaiah, Susan C Guba, Karim A Benhadji, Christopher A Slapak
  • Drug Design Development and Therapy, August 2015, Dove Medical Press
  • DOI: 10.2147/dddt.s86621

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication

http://dx.doi.org/10.2147/dddt.s86621

The following have contributed to this page: Dr Michael Lahn

In partnership with: